Board-controlled extension affects remaining locked shares through 2026, reflecting governance decisions around share release.

Management indicated the Board may end the 100% lock-up earlier and implement staged sale options or other mechanisms.

Interim and open-label FLAMINGO-01 data show preliminary signals of strong immune responses and a notable reduction in recurrence, including about an 80% decrease in non-HLA-A*02 arms after the PIS, with similar trends to Phase IIb results, though data are preliminary.

The extension aligns short-term insiders with the company’s long-term investors to support the FLAMINGO-01 Phase III trial of GLSI-100, an immunotherapy aimed at preventing breast cancer recurrences.

FLAMINGO-01 is an open-label Phase III trial led by Baylor College of Medicine, evaluating GLSI-100 (GP2 + GM-CSF) in HER2-positive patients with residual disease or high risk after standard therapy, with plans to enroll up to 150 sites globally and randomize about 500 HLA-A*02 patients to GLSI-100 versus placebo, plus additional patients with other HLA types.

GLSI-100 targets the HER2 protein to prevent recurrences and is discussed within the context of broader breast cancer statistics and HER2-positivity prevalence.

The market reaction was positive, with GLSI stock rising roughly 5.25% on the news and trading volume about 2.9 times the 20-day average, as the price hovered near $21.77.

The press release includes forward-looking statements and cautions that results are preliminary and subject to risks disclosed in SEC filings, with contact details for investor relations and PR.

Standard forward-looking statements and risk disclosures are included, with specifics available in Greenwich LifeSciences’ 2024 Form 10-K and other SEC filings.

The release provides investor and public relations contact information alongside the usual forward-looking statements and risk disclosures.

Historical updates on trial progress and strategic funding are noted, with the lock-up extension fitting a pattern of governance moves tied to long-term trial development.

Share lock-up for directors, officers and pre-IPO investors has been extended to September 30, 2026, with the potential for earlier termination or alternative sale mechanisms such as leak-out plans or 10b5-1 trading plans.